Characterization of broadly neutralizing antibody responses to HIV-1 in a cohort of long term non-progressors
González, Nuria (Instituto de Salud Carlos III)
McKee, Krisha (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Washington, United States of America)
Lynch, Rebecca M. (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Washington, United States of America)
Georgiev, Ivelin S. (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Washington, United States of America)
Jimenez, Laura (Instituto de Salud Carlos III)
Grau, Eulàlia (Institut Germans Trias i Pujol. Institut de Recerca de la Sida IrsiCaixa)
Yuste, Eloísa (Hospital Clínic i Provincial de Barcelona)
Kwong, Peter D. (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Washington, United States of America)
Mascola, John R. (Vaccine Research Center, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Washington, United States of America)
Alcami, Jose (Instituto de Salud Carlos III)

Data:	2018
Resum:	Only a small fraction of HIV-1-infected patients develop broadly neutralizing antibodies (bNAbs), a process generally associated to chronic antigen stimulation. It has been described that rare aviremic HIV-1-infected patients can generate bNAbs but this issue remains controversial. To address this matter we have assessed bNAb responses in a large cohort of long-term non-progressors (LTNPs) with low or undetectable viremia. Samples from the LTNP cohort of the Spanish AIDS Research Network (87 elite and 42 viremic controllers) and a control population of 176 viremic typical-progressors (TPs) were screened for bNAbs using Env-recombinant viruses. bNAb specificities were studied by ELISA using mutated gp120, neutralization assays with mutated viruses, and peptide competition. Epitope specificities were also elucidated from the serum pattern of neutralization against a panel of diverse HIV-1 isolates. Broadly neutralizing sera were found among 9. 3% LTNPs, both elite (7%) and viremic controllers (14%). Within the broadly neutralizing sera, CD4 binding site antibodies were detected by ELISA in 4/12 LTNPs (33%), and 16/33 of TPs (48%). Anti-MPER antibodies were detected in 6/12 LTNPs (50%) and 14/33 TPs (42%) whereas glycan-dependent HIV-1 bNAbs were more frequent in LTNPs (11/12, 92%) as compared to TPs (12/33, 36%). A good concordance between standard serum mapping and neutralization-based mapping was observed. LTNPs, both viremic and elite controllers, showed broad humoral immune responses against HIV-1, including activity against many major epitopes involved in bNAbs-mediated protection.
Ajuts:	Ministerio de Economía y Competitividad PI16CIII/0034 European Commission 681137
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Publicat a:	PloS one, Vol. 13 (march 2018) , ISSN 1932-6203

DOI: 10.1371/journal.pone.0193773
PMID: 29558468

18 p, 4.2 MB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut d'Investigació en Ciencies de la Salut Germans Trias i Pujol (IGTP)
Articles > Articles de recerca
Articles > Articles publicats